Related Experiment Video

Updated: May 25, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.7K

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants

Andreea Calomfirescu-Avramescu1, Adrian Ioan Toma2, Claudia Mehedințu1,3

  • 1Filantropia Clinical Hospital, 011171 Bucharest, Romania.

Vaccines
|February 26, 2025
PubMed

Insights

Romania

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Romania initiated a Respiratory Syncytial Virus (RSV) immunoprophylaxis program in 2022.
  • The program targets high-risk infants, including preterm infants and those with congenital heart defects or chronic lung disease.
  • Palivizumab is the monoclonal antibody used for RSV prevention in this program.

Purpose of the Study:

  • To evaluate the adherence to Palivizumab treatment in Romania's RSV immunoprophylaxis program.
  • To monitor the growth of the program in terms of patient and healthcare provider enrollment.
  • To identify factors affecting treatment adherence.

Main Methods:

  • Monitoring patient and specialist enrollment numbers from August 2022 to March 2024.
  • Assessing Palivizumab dose adherence through telephone interviews with enrolled patients.
  • Identifying reasons for decreased adherence to the full vaccination sequence.

Main Results:

  • 1903 patients and 233 specialists were enrolled between August 2022 and March 2024.
  • Adherence decreased with the number of doses: 99% for one dose, 73% for two, 47% for three, 35% for four, and 22% for five doses.
  • Several factors were identified as contributing to reduced adherence.

Conclusions:

  • The RSV immunoprophylaxis program is highly valued by physicians and caregivers.
  • The program effectively educates parents on RSV prevention.
  • Monoclonal antibody administration for RSV prevention is facilitated by this program.
Abstract

Keywords:
immunoprophylaxis for RSVpalivizumabrespiratory syncytial virus

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Related Concept Videos

Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
205
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
113
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
116
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
158
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
159
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
151